Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: Biodistribution, biokinetics and immediate toxicities
Buchmann, I × Bunjes, D Kotzerke, L Martin, H Glatting, G Seitz, U Rattat, Dirk Buck, A Dohner, H Reske, SN #
Mary ann liebert inc publ
Cancer biotherapy and radiopharmaceuticals vol:17 issue:2 pages:151-163
Background. Stein cell transplantation (SCT) is potentially curative for high-risk leukemia patients. Conditioning regimens affect relapse rate and treatment-related mortality. We evaluated biodistribution, radiation absorbed organ doses and immediate toxicities of myeloablative radioimmunotherapy with marrow selective (188)rhenium (Re-188)-labeled anti-CD66 monoclonal antibody (mAb).